Changes in brain activity in the anterior cingulate cortex could be the best predictor of depression severity.
A new technique that uses ultrafast fMRI is able to capture brain activity at sub-second levels. The technique allows for real-time monitoring of the brain under stimulation conditions.
Deep brain stimulation at the intersection of two fiber bundles linked to memory formation appears to alleviate symptoms of Alzheimer's disease.
Deep brain stimulation can improve symptoms of OCD by up to 50% and provide substantial improvements in two out of three sufferers.
Deep brain stimulation of the nucleus accumbens helps control symptoms of binge eating disorder and assists in weight loss.
Deep brain stimulation applied to a small brain area associated with reward and motivation resulted in metabolic brain changes over 12 months post-implantation and alleviated some symptoms of depression for those with treatment-resistant depression.
Using lesion network mapping, researchers identified brain circuits associated with addiction remission. The findings provide a new target for the development of treatments for addiction.
A new computer model shows the beneficial effects of deep brain stimulation arise from how it interrupts the cycle promoting runway beta in a circuit loop between the subthalamic nucleus and striatum.
Combining deep-brain stimulation with intracranial EEG, researchers achieved an individualized understanding of specific brain networks that contributed to an individual's depression symptoms and identified stimulation patterns best suited to each patient for symptom relief.
A new, improved DBS technique that targets specific subpopulations of neurons in the globus pallidus with short bursts of stimulation shows promising results as a treatment for Parkinson's disease.
A modified deep brain stimulation devise that delivers on-demand stimulation when it recognizes changes in brain patterns provides immediate and long-term relief for depression sufferers.
Deep brain stimulation appears to be safe, effective, and provides symptom improvements for at least one year in patients with treatment-resistant schizophrenia.
